0
Signin
countryflagUS

18889881171

AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%

Nymox Pharmaceutical Corporation

Healthcare US NYMXF

0.139USD
0.04(39.00%)

Last update at 2024-12-19T15:17:00Z

Day Range

0.140.14
LowHigh

52 Week Range

0.121.27
LowHigh

Fundamentals

  • Previous Close 0.10
  • Market Cap91.72M
  • Volume1358
  • P/E Ratio-
  • Dividend Yield3.28%
  • EBITDA-2.39100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.06

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -6.57600M -12.53700M -11.73800M -13.16200M
Minority interest - - - -
Net income -6.57600M -12.53700M -11.73800M -13.16200M
Selling general administrative 2.88M 5.85M 3.60M 6.01M
Selling and marketing expenses - - - -
Gross profit 0.00000M 0.00000M 0.00100M 0.06M
Reconciled depreciation 0.25M 0.25M 0.27M 0.56M
Ebit -6.65200M -12.50400M -11.72000M -13.32500M
Ebitda -6.28400M -12.24400M -11.42900M -12.55900M
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -6.65200M -12.50400M -11.72000M -13.32500M
Other operating expenses - - - -
Interest expense 0.04M 0.04M 0.04M 0.04M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00100M 0.00800M 0.03M 0.21M
Net interest income -0.04200M -0.03100M -0.01500M 0.17M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 0.00000M 0.00000M 0.00500M 0.12M
Total operating expenses 6.65M 12.50M 11.72M 13.44M
Cost of revenue 0.00000M 0.00000M 0.00400M 0.06M
Total other income expense net 0.12M -0.00200M -0.00300M -0.01200M
Discontinued operations - - - -
Net income from continuing ops -6.57600M -12.53700M -11.73800M -13.16200M
Net income applicable to common shares -6.57600M -12.53700M -11.73800M -13.16200M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1.62M 1.44M 4.34M 5.49M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.03M 0.03M 0.03M 0.03M
Total liab 2.11M 1.95M 2.20M 2.04M
Total stockholder equity -0.48200M -0.50600M 2.15M 3.45M
Deferred long term liab - - - -
Other current liab - - 0.05M -
Common stock 171.67M 165.06M 151.72M 136.55M
Capital stock 171.67M 165.06M 151.72M 136.55M
Retained earnings -199.13800M -192.56200M -180.02500M -168.28700M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 1.40M 0.83M 3.61M 5.24M
Cash and equivalents - - - -
Total current liabilities 2.11M 1.79M 1.97M 2.04M
Current deferred revenue - - - -
Net debt - - - -
Short term debt - - - -
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity - -0.58900M -0.58900M -0.58900M
Property plant equipment 0.17M 0.41M 0.45M 0.16M
Total current assets 1.46M 1.04M 3.89M 5.33M
Long term investments - - - -
Net tangible assets -0.48200M -0.50600M 2.15M 3.45M
Short term investments - - - -
Net receivables 0.01000M 0.01M 0.02M 0.02M
Long term debt - - - -
Inventory 0.00000M 0.03M 0.03M 0.02M
Accounts payable 1.93M 1.27M 1.40M 1.63M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 0.17M 0.41M 0.45M 0.16M
Capital lease obligations 0.17M 0.39M 0.43M 0.15M
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00000M -0.00600M -0.01300M 0.00000M
Change to liabilities 0.38M -0.16500M -0.17200M 0.82M
Total cashflows from investing activities - -0.00600M -0.01300M -0.01300M
Net borrowings -0.22900M -0.23800M -0.26500M -0.27700M
Total cash from financing activities 5.78M 7.04M 8.42M 4.72M
Change to operating activities 0.12M 0.02M -0.13000M -0.00600M
Net income -6.57600M -12.53700M -11.73800M -13.16200M
Change in cash 0.57M -2.78100M -1.62800M -2.70700M
Begin period cash flow 0.83M 3.61M 5.24M 7.95M
End period cash flow 1.40M 0.83M 3.61M 5.24M
Total cash from operating activities -5.20500M -9.82000M -10.03700M -7.43000M
Issuance of capital stock 6.01M 7.28M 8.69M 5.00M
Depreciation 0.25M 0.23M 0.26M 0.26M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory 0.00000M 0.00000M -0.01100M 0.02M
Change to account receivables 0.00300M 0.00700M -0.00100M -0.00400M
Sale purchase of stock - - - -
Other cashflows from financing activities - - - -
Change to netincome 0.63M 2.62M 1.76M 4.65M
Capital expenditures 0.00000M 0.00600M 0.01M 0.01M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.49M -0.14000M -0.31400M 0.83M
Stock based compensation 0.59M 2.60M 1.75M 3.01M
Other non cash items - - - 1.33M
Free cash flow -5.20500M -9.82600M -10.05000M -7.43000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
NYMXF
Nymox Pharmaceutical Corporation		 0.04 39.00% 0.14 - - - -
NVO
Novo Nordisk A/S		 -2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.